Two Sigma Securities LLC Invests $3.05 Million in Zoetis Inc. $ZTS

Two Sigma Securities LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 42,431 shares of the company’s stock, valued at approximately $3,049,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Private Harbour Investment Management & Counsel LLC increased its holdings in Zoetis by 1.6% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 12,106 shares of the company’s stock worth $870,000 after purchasing an additional 193 shares in the last quarter. Flputnam Investment Management Co. boosted its stake in shares of Zoetis by 1,595.7% during the second quarter. Flputnam Investment Management Co. now owns 30,218 shares of the company’s stock valued at $2,171,000 after purchasing an additional 28,436 shares in the last quarter. Davidson Investment Advisors boosted its stake in shares of Zoetis by 107.8% during the second quarter. Davidson Investment Advisors now owns 111,868 shares of the company’s stock valued at $8,039,000 after purchasing an additional 58,044 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Zoetis by 8.1% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 84,210 shares of the company’s stock worth $6,051,000 after purchasing an additional 6,327 shares during the last quarter. Finally, Wedbush Securities Inc. increased its stake in shares of Zoetis by 12.1% in the second quarter. Wedbush Securities Inc. now owns 10,238 shares of the company’s stock valued at $736,000 after buying an additional 1,105 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.1%

Shares of ZTS stock opened at $77.45 on Monday. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock has a market cap of $32.00 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.80 and a beta of 0.73. The stock has a 50-day moving average of $75.57 and a 200-day moving average of $95.40.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the firm earned $1.76 earnings per share. The firm’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. UBS Group reduced their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research report on Tuesday, August 25th. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Finally, Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $107.43.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.